Comparative Pharmacology
Head-to-head clinical analysis: SAXENDA versus TRULICITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SAXENDA versus TRULICITY.
SAXENDA vs TRULICITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and promotes satiety via central GLP-1 receptor activation.
Glucagon-like peptide-1 (GLP-1) receptor agonist. Increases glucose-dependent insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Subcutaneous injection once daily, starting at 0.6 mg and titrating weekly by 0.6 mg increments to a maintenance dose of 3.0 mg.
1.5 mg subcutaneously once weekly, with or without food.
None Documented
None Documented
11–13 hours (subcutaneous). Steady-state is reached after 3–5 once-daily doses.
Terminal elimination half-life approximately 5 days (112–120 hours) after subcutaneous administration, supporting once-weekly dosing.
Renal excretion of intact liraglutide is minimal; approximately 6% is excreted as intact liraglutide in urine. The remainder is metabolized and eliminated via the kidneys and feces, with no single metabolite accounting for >10% of the dose.
Renal: negligible (intact peptide not excreted in urine); Biliary/fecal: peptide backbone catabolized via proteolysis, with amino acids recycled; no biliary excretion of intact drug.
Category C
Category C
GLP-1 Receptor Agonist, Anti-obesity
GLP-1 Receptor Agonist